3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vomiting
13
Nausea
6
Neoplasms
5
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Melanoma
1
Gynecologic Cancer
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Educational Status
3
pembrolizumab
2
anlotinib
2
Therapeutic Touch
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy
2
Palliative Care
2
Methods
2
Interviews as Topic
2
Early Intervention, Educational
2
Carboplatin
2
temsirolimus
1
olaparib
1
niraparib
1
fosaprepitant
1
argatroban
1
Topotecan
1
Thrombopoietin
1
Surgical Procedures, Operative
1
Practice Guidelines as Topic
1
Palonosetron
1
Paclitaxel
1
Nivolumab
1
Ipilimumab
1
Heparin, Low-Molecular-Weight
1
Filgrastim
1
Dimenhydrinate
1
Diffusion
1
Diet
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Genital Neoplasms, Female
×
fosaprepitant
×
Clear all
NCT01074697
2015-04-24
GAND-emesis
Odense University Hospital
Phase 3
Completed
246 enrolled